Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

The study conducted by IIT Roorkee is supported by the Indian Council of Medical Research (ICMR). It has been published in a ...

Scientists at IIT Roorkee have achieved a major breakthrough by identifying a potential drug for the treatment of chikungunya ...

This fixed-dose tablet combines 600mg efavirenz, 200mg emtricitabine (FTC), and 245mg tenofovir disoproxil fumarate (TDF). Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), ...

IIT Roorkee researchers have discovered that Efavirenz, an HIV drug, may help treat Chikungunya by reducing virus replication in lab tests and mice models. While promising, clinical trials are needed ...

Efavirenz (EFV), brand-named drugs such as Sustiva, is an antiretroviral drug utilized mostly for HIV/AIDS treatment and prevention. Efavirenz is a category of drugs that fall under non-nucleoside ...

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS.

The research suggests that Efavirenz, a drug commonly used to treat HIV, may help reduce the replication of the Chikungunya virus. With promising results observed in both laboratory settings and ...

Efavirenz/emtricitabine/tenofovir disoproxil fumarate are medications used to treat HIV. They are antiretroviral drugs combined in one pill, taken once a day. Two of the drugs (emtricitabine and ...